185 related articles for article (PubMed ID: 37540262)
21. Association of the advanced lung cancer inflammation index (ALI) with immune checkpoint inhibitor efficacy in patients with advanced non-small-cell lung cancer.
Mountzios G; Samantas E; Senghas K; Zervas E; Krisam J; Samitas K; Bozorgmehr F; Kuon J; Agelaki S; Baka S; Athanasiadis I; Gaissmaier L; Elshiaty M; Daniello L; Christopoulou A; Pentheroudakis G; Lianos E; Linardou H; Kriegsmann K; Kosmidis P; El Shafie R; Kriegsmann M; Psyrri A; Andreadis C; Fountzilas E; Heussel CP; Herth FJ; Winter H; Emmanouilides C; Oikonomopoulos G; Meister M; Muley T; Bischoff H; Saridaki Z; Razis E; Perdikouri EI; Stenzinger A; Boukovinas I; Reck M; Syrigos K; Thomas M; Christopoulos P
ESMO Open; 2021 Oct; 6(5):100254. PubMed ID: 34481329
[TBL] [Abstract][Full Text] [Related]
22. Venous thromboembolism events in patients with advanced cancer on immune checkpoint inhibitors.
Kartolo A; Yeung C; Moffat GT; Hanna L; Hopman W; Baetz T
Immunotherapy; 2022 Jan; 14(1):23-30. PubMed ID: 34758641
[No Abstract] [Full Text] [Related]
23. Venous thromboembolism among patients with advanced lung cancer randomized to prinomastat or placebo, plus chemotherapy.
Behrendt CE; Ruiz RB
Thromb Haemost; 2003 Oct; 90(4):734-7. PubMed ID: 14515196
[TBL] [Abstract][Full Text] [Related]
24. A Phase 2 Study of Docetaxel, Ramucirumab, and Pembrolizumab for Patients With Metastatic or Recurrent Non-Small-Cell Lung Cancer (NSCLC) who Progressed on Platinum-Doublet and PD-1/PD-L1 Blockade.
Osta BE; Carlisle J; Steuer C; Pakkala S; Leal T; Dhodapkar M; Liu Y; Chen Z; Owonikoko T; Ramalingam S
Clin Lung Cancer; 2022 Nov; 23(7):e400-e404. PubMed ID: 35863963
[TBL] [Abstract][Full Text] [Related]
25. Prognostic Factors of Second-line Immune Checkpoint Inhibitors in Patients With Advanced-stage Non-Small Cell Lung Cancer: A Multicenter, Retrospective Study.
Roh J; Eom JS; Lee MK; Kim J; Jang T; Yoon SH; Son CH; Lee HK; Kim HK; Lee SY; Shin KC; Kim MH
Am J Clin Oncol; 2021 Jul; 44(7):356-360. PubMed ID: 34014843
[TBL] [Abstract][Full Text] [Related]
26. First-line PD-1/PD-L1 inhibitors plus chemotherapy versus bevacizumab plus chemotherapy for advanced non-squamous non-small cell lung cancer: A Bayesian network meta-analysis of randomized controlled trials.
Zhai J; Lu J; Zhang Z; Wang Y; Li X; Zhang S; Mu S; Zhi X; Ge X; Lu D; Hu Y; Wang J
Cancer Med; 2022 May; 11(10):2043-2055. PubMed ID: 35315579
[TBL] [Abstract][Full Text] [Related]
27. Best regimens for treating chemo-naïve incurable squamous non-small cell lung cancer with a programmed death-ligand 1 tumor proportion score of 1%-49%: A network meta-analysis.
Fukuda N; Horita N; Namkoong H; Kaneko A; Somekawa K; Tagami Y; Watanabe K; Hara Y; Kobayashi N; Kaneko T
Thorac Cancer; 2022 Jan; 13(1):84-94. PubMed ID: 34791815
[TBL] [Abstract][Full Text] [Related]
28. Characteristics and Outcomes of Cancer Patients With Venous Thromboembolic Events After Treatment With Immune Checkpoint Inhibitors.
Dutra B; Garcia-Rodriguez V; Garcia R; Szafron D; Abraham F; Khurana S; Lockhart J; Amin R; Wang Y; Thomas A
Am J Clin Oncol; 2023 Mar; 46(3):94-100. PubMed ID: 36735530
[TBL] [Abstract][Full Text] [Related]
29. Increased risk of venous and arterial thromboembolism in patients with colorectal cancer receiving cetuximab-based combination chemotherapy: A population-based study in Korea.
Yhim HY; Lee J; Kim KH; Kim SA; Lee JY; Hwang HG; Hong J; Lee JO; Bang SM
Thromb Res; 2023 Nov; 231():50-57. PubMed ID: 37804738
[TBL] [Abstract][Full Text] [Related]
30. Clinical impact of venous thromboembolism in non-small cell lung cancer patients receiving immunotherapy.
Bjørnhart B; Kristiansen C; Asmussen J; Hansen KH; Wedervang K; Jørgensen TL; Herrstedt J; Schytte T
Thromb Res; 2023 Jan; 221():164-172. PubMed ID: 36396518
[TBL] [Abstract][Full Text] [Related]
31. Immune Checkpoint Inhibitor Is Associated with Improved Survival in Advanced Non-small Cell Lung Cancer Occurring in Patients with Autoimmune Disease.
Ihara Y; Sawa K; Imai T; Nonomiya Y; Shimomura Y; Ishihara A; Shintani A
Biol Pharm Bull; 2024; 47(2):454-461. PubMed ID: 38382998
[TBL] [Abstract][Full Text] [Related]
32. Risk of pneumonitis in non-small cell lung cancer patients with preexisting interstitial lung diseases treated with immune checkpoint inhibitors: a nationwide retrospective cohort study.
Sawa K; Sato I; Takeuchi M; Kawakami K
Cancer Immunol Immunother; 2023 Mar; 72(3):591-598. PubMed ID: 35994088
[TBL] [Abstract][Full Text] [Related]
33. Concomitant Proton Pump Inhibitor Use With Pembrolizumab Monotherapy vs Immune Checkpoint Inhibitor Plus Chemotherapy in Patients With Non-Small Cell Lung Cancer.
Kawachi H; Yamada T; Tamiya M; Negi Y; Goto Y; Nakao A; Shiotsu S; Tanimura K; Takeda T; Okada A; Harada T; Date K; Chihara Y; Hasegawa I; Tamiya N; Ishida M; Katayama Y; Morimoto K; Iwasaku M; Tokuda S; Kijima T; Takayama K
JAMA Netw Open; 2023 Jul; 6(7):e2322915. PubMed ID: 37432682
[TBL] [Abstract][Full Text] [Related]
34. Immune checkpoint inhibitor-associated thrombosis in patients with bladder and kidney cancer: a study of the Spanish Society of Medical Oncology (SEOM) thrombosis and cancer group.
Sánchez Cánovas M; Fernández Garay D; Adoamnei E; Guirao García E; López Robles J; Cacho Lavin D; Martínez de Castro E; Campos Balea B; Garrido Fernández A; Fernández Pérez I; Ferrández Arias A; Suarez N; Quintanar Verduguez T; Lobo de Mena M; Rodríguez L; Gutierrez D; Martín Fernández de Soiginie AM; García Adrián S; Ferrer Pérez AI; Delgado Heredia MJ; Muñoz Lerma A; Luque R; Mazariegos Rubí M; Rúperez Blanco AB; García Escobar I; Mendiola J; Muñoz Martín AJ
Clin Transl Oncol; 2023 Oct; 25(10):3021-3031. PubMed ID: 37036596
[TBL] [Abstract][Full Text] [Related]
35. Real-World Survival of First-Line Immune Checkpoint Inhibitor Treatment Versus Chemotherapy in Older Patients With Non-Small-Cell Lung Cancer and Synchronous Brain Metastases.
Mahashabde R; Bhatti SA; Martin BC; Painter JT; Rodriguez A; Ying J; Li C
JCO Oncol Pract; 2023 Nov; 19(11):1009-1019. PubMed ID: 37729600
[TBL] [Abstract][Full Text] [Related]
36. Comparative safety of immune checkpoint inhibitors and chemotherapy in advanced non-small cell lung cancer: A systematic review and network meta-analysis.
Chen CY; Huang CH; Chen WC; Huang MS; Wei YF
Int Immunopharmacol; 2022 Jul; 108():108848. PubMed ID: 35597121
[TBL] [Abstract][Full Text] [Related]
37. First-line immune-checkpoint inhibitor combination therapy for chemotherapy-eligible patients with metastatic urothelial carcinoma: A systematic review and meta-analysis.
Mori K; Pradere B; Moschini M; Mostafaei H; Laukhtina E; Schuettfort VM; Sari Motlagh R; Soria F; Teoh JYC; Egawa S; Powles T; Shariat SF;
Eur J Cancer; 2021 Jul; 151():35-48. PubMed ID: 33962359
[TBL] [Abstract][Full Text] [Related]
38. Efficacy and safety of maintenance immune checkpoint inhibitors with or without pemetrexed in advanced non-squamous non-small cell lung cancer: a retrospective study.
Gu X; Shi Z; Shao L; Zhang Y; Zhang Y; Song Z; Wang W; Lou G
BMC Cancer; 2022 May; 22(1):576. PubMed ID: 35606756
[TBL] [Abstract][Full Text] [Related]
39. Venous thromboembolism and nonsmall cell lung cancer: a pooled analysis of National Cancer Institute of Canada Clinical Trials Group trials.
Hicks LK; Cheung MC; Ding K; Hasan B; Seymour L; Le Maître A; Leighl NB; Shepherd FA
Cancer; 2009 Dec; 115(23):5516-25. PubMed ID: 19711465
[TBL] [Abstract][Full Text] [Related]
40. Association of tumour burden with the efficacy of programmed cell death-1/programmed cell death ligand-1 inhibitors for treatment-naïve advanced non-small-cell lung cancer.
Suzuki S; Haratani K; Hayashi H; Chiba Y; Tanizaki J; Kato R; Mitani S; Kawanaka Y; Kurosaki T; Hasegawa Y; Okabe T; Tanaka K; Akashi Y; Ozaki T; Nishio K; Ito A; Nakagawa K
Eur J Cancer; 2022 Jan; 161():44-54. PubMed ID: 34922263
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
